In the last trading session, 1.05 million Lyell Immunopharma Inc (NASDAQ:LYEL) shares changed hands as the company’s beta touched -0.47. With the company’s per share price at $0.94 changed hands at -$0.06 or -6.14% during last session, the market valuation stood at $262.08M. LYEL’s last price was a discount, traded about -246.81% off its 52-week high of $3.26. The share price had its 52-week low at $0.85, which suggests the last value was 9.57% up since then. When we look at Lyell Immunopharma Inc’s average trading volume, we note the 10-day average is 1.54 million shares, with the 3-month average coming to 1.26 million.

Analysts gave the Lyell Immunopharma Inc (LYEL) stock a consensus recommendation rating of Hold, calculated at a mean rating of 3.33. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended LYEL as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. Lyell Immunopharma Inc’s EPS for the current quarter is expected to be 0.

Lyell Immunopharma Inc (NASDAQ:LYEL) trade information

Instantly LYEL was in red as seen at the end of in last trading. With action 2.82%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -51.62%, with the 5-day performance at 2.82% in the green. However, in the 30-day time frame, Lyell Immunopharma Inc (NASDAQ:LYEL) is -16.20% down. Looking at the short shares, we see there were 9.6 million shares sold at short interest cover period of 5.18 days.

The consensus price target for the stock as assigned by Wall Street analysts is 7, meaning bulls need an upside of 86.57% from its current market value. According to analyst projections, LYEL’s forecast low is 1 with 12 as the target high. To hit the forecast high, the stock’s price needs a -1176.6% plunge from its current level, while the stock would need to soar -6.38% for it to hit the projected low.

Lyell Immunopharma Inc (LYEL) estimates and forecasts

Data shows that the Lyell Immunopharma Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -62.31% over the past 6 months, a 13.98% in annual growth rate that is considerably lower than the industry average of 16.60%. Year-over-year growth is forecast to reach -74.62% down from the last financial year.

The company’s revenue for the corresponding quarters a year ago was 13k. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -100.00%. The estimates for the next quarter sales put growth at 0.00%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -15.28%. The 2024 estimates are for Lyell Immunopharma Inc earnings to increase by 14.52%, but the outlook for the next 5-year period is at -7.90% per year.

LYEL Dividends

Lyell Immunopharma Inc is expected to release its next quarterly earnings report in January.

Lyell Immunopharma Inc (NASDAQ:LYEL)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 14.06% of Lyell Immunopharma Inc shares while 61.65% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 71.73%. There are 61.65% institutions holding the Lyell Immunopharma Inc stock share, with MWG MANAGEMENT LTD. the top institutional holder. As of 2024-06-30, the company held 7.9301% of the shares, roughly 20.16 million LYEL shares worth $29.24 million.

ORLAND PROPERTIES LTD holds the second largest percentage of outstanding shares, with 5.9366% or 15.09 million shares worth $21.89 million as of 2024-06-30.